CE Mark for Seal-V vascular sealant

PRIVATE start-up Sealantis Ltd. (Haifa, Israel), which develops alga-mimetic tissue adhesives, said it has received the CE Mark for Seal-V, its vascular sealant.

Seal-V is a protein-free bioresorbable sealant, intended to achieve hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels such as the carotid, femoral, brachial and iliac arteries.

Being alga-mimetic it has an intrinsic ability to bind strongly to both native blood vessels and synthetic grafts, even in wet and moist conditions. In addition, the protein-free composition relieves Seal-V from risks associated with the use of protein-based products. Unlike hemostats, which are designed to cause blood to clot, Seal-V? is not dependent on the presence of blood in order to be effective, and can be used as a prophylactic sealant.

"We are excited to be able to introduce Seal-V to the European market and to provide surgeons with a new and better option for controlling bleeding from suture-lines," said Mr.Tomer Fuchs, Sealantis CEO. Mr. Fuchs recently joined Sealantis, after serving over two decades in lead executive positions in global companies including Medtronic Ventor, Anorad and Vishay.

"Sealantis has been working closely with surgeons to leverage the extraordinary capabilities of its alga-mimetic technology and design products that will be strongly positioned in the multibillion dollars market of wound closure," said Dr. Zeev Gilkis, Sealantis chairman.

In addition to Seal-V, Sealantis has a pipeline of advanced solutions for a variety of clinical needs. Among them is a gastro-intestinal sealant, designed to prevent leakage of intestinal content from anastomoses, a potentially fatal complication of GI surgery; an adhesive for space obliteration in esthetic surgeries, which can significantly reduce the recovery time from face and body lifts and innovative combination devices for site-specific drug delivery.

Sealantis, founded in 2007 by Prof. Havazelet Bianco-Peled, and is funded by the Alfred Mann Institute at the Technion (AMIT), is currently working on strategic partnerships towards the coming market launch of Seal-V.